Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
Caicun Zhou(Tongji University), Pasi A. Jänne(Harvard University), Veronica Bunn(Takeda (United States)), Sang‐We Kim(Ulsan College), Danny Nguyen(Harbin Medical University), James Chih‐Hsin Yang(National Taiwan University Hospital), Minal Mehta(Millennium Engineering and Integration (United States)), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Suresh S. Ramalingam(Emory University), Enriqueta Felip(Institut Català d'Ornitologia), Sylvie Vincent(Takeda (United States)), Tae Min Kim(Seoul National University Hospital), Shu Jin(Millennium Engineering and Integration (United States)), Celina Griffin(Takeda (United States)), Tarek Mekhail(AdventHealth Orlando), Jianchang Lin(Millennium Engineering and Integration (United States)), M.R. García Campelo(Complexo Hospitalario Universitario A Coruña), Huamao Mark Lin(Takeda (United States))
Cited by 289
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k